Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/123290
Title: | Optimization, biopharmaceutical profile and therapeutic efficacy of pioglitazone-loaded PLGA-PEG nanospheres as a novel strategy for ocular inflammatory disorders. |
Author: | Silva Abreu, Marcelle Calpena Campmany, Ana Cristina Espina García, Marta Silva, Amélia M. Gimeno Sandig, Álvaro Egea Gras, Ma. Antonia García López, María Luisa |
Keywords: | Sistemes d'alliberament de medicaments Nanopartícules Agents antiinflamatoris Oftalmologia Drug delivery systems Nanoparticles Antiinflammatory agents Ophthalmology |
Issue Date: | 3-Jan-2018 |
Publisher: | Springer Science + Business Media |
Abstract: | PURPOSE: The main goal of this study was to encapsulate Pioglitazone (PGZ), in biodegradable polymeric nanoparticles as a new strategy for the treatment of ocular inflammatory processes. METHODS: To improve their biopharmaceutical profile for the treatment of ocular inflammatory disorders, nanospheres (NSs) of PGZ were formulated by factorial design with poly (lactic-co-glycolic acid) polyethylene glycol (PLGA-PEG). Interactions drug-polymer have been carried out by spectroscopic (X-ray spectroscopy, FTIR) and thermal methods (DSC). The PGZ-NSs were tested for their in vitro release profile, cytotoxicity, and ocular tolerance (HET-CAM® test); ex vivo corneal permeation, and in vivo inflammatory prevention and bioavailability. RESULTS: The optimized system showed a negative surface charge of -13.9 mV, an average particle size (Zav) of around 160 nm, a polydispersity index (PI) below 0.1, and a high encapsulation efficiency (EE) of around 92%. According to the DSC results, the drug was incorporated into the NSs polymeric matrix. The drug release was sustained for up to 14 h. PGZ-NSs up to 10 μg/ml exhibited no retinoblastoma cell toxicity. The ex vivo corneal and scleral permeation profiles of PGZ-NSs showed that retention and permeation through the sclera were higher than through the cornea. Ocular tolerance in vitro and in vivo demonstrated the non-irritant character of the formulation. CONCLUSION: The in vivo anti-inflammatory efficacy of developed PGZ-NSs indicates this colloidal system could constitute a new approach to prevent ocular inflammation. KEYWORDS: PLGA-PEG; drug delivery; nanospheres; ocular anti-inflammatory efficacy; pioglitazone |
Note: | Versió postprint del document publicat a: https://doi.org/10.1007/s11095-017-2319-8 |
It is part of: | Pharmaceutical Research, 2018, vol. 35, num. 1, p. 11 |
URI: | http://hdl.handle.net/2445/123290 |
Related resource: | https://doi.org/10.1007/s11095-017-2319-8 |
ISSN: | 0724-8741 |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
676270.pdf | 860.37 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.